北美人群中I期子宫内膜癌的广泛淋巴血管间隙浸润风险是否与PORTEC研究相似?一项单机构研究
该单机构回顾性研究纳入438例pT1a-b期子宫内膜样子宫内膜癌患者,旨在量化北美人群广泛淋巴血管间隙浸润(LVSI)的发生率并分析LVSI程度与淋巴结转移的相关性。结果显示总体队列中广泛LVSI发生率为16.0%,符合PORTEC-1入组标准的亚组为25.1%,均高于PORTEC报告的4.8%,且LVSI程度与淋巴结受累相关。作者认为需多机构数据验证。
要点
- 总体队列中广泛LVSI发生率为16.0%,符合PORTEC-1标准的亚组为25.1%。
- 无LVSI、局灶LVSI和广泛LVSI患者的淋巴结受累率分别为3.3%、7.5%(OR 2.4)和15.2%(OR 5.3),p = .005。
- 广泛LVSI发生率比PORTEC报告高3至5倍,作者认为需多机构数据确认。
核心结论
- 本研究中广泛LVSI的发生率比PORTEC报告高3至5倍,且与淋巴结受累相关。
- 作者认为这一结果对三级LVSI报告系统的可重复性提出疑问,并强调需要PORTEC之外的多机构数据来确认本研究发现。
研究设计与样本
- 单机构回顾性研究,纳入438例临床局限于子宫、经手术分期证实为pT1a-b期的子宫内膜样子宫内膜癌患者。
- 采用二元逻辑回归评估淋巴结受累(定义为孤立肿瘤细胞、微转移或宏转移)的预测因素。
主要发现
- 总体队列中无LVSI、局灶LVSI和广泛LVSI的发生率分别为67.4%、16.7%和16.0%。
- 符合PORTEC-1入组标准的亚组(n = 195)中无LVSI、局灶LVSI和广泛LVSI的发生率分别为50.8%、24.1%和25.1%。
- 接受手术淋巴结评估的患者(79.2%,n = 347)中,无LVSI、局灶LVSI和广泛LVSI患者的淋巴结受累率分别为3.3%、7.5%(OR 2.4)和15.2%(OR 5.3),p = .005。
- PORTEC-1队列中观察到相似趋势。
- LVSI程度与淋巴结转移的疾病负荷相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A pooled analysis of PORTEC-1 & 2 identified substantial lymphovascular space invasion (LVSI) in 4.8% of patients, which predicted for pelvic recurrence, distant metastasis, and overall survival. Our institution implemented the PORTEC three-tier system of LVSI reporting (absent, focal, or substantial). We aimed to quantify the incidence of substantial LVSI in a North American population and to correlate extent of LVSI with lymph node (LN) involvement. METHODS: A retrospective review was conducted on patients with clinically uterine-confined, endometrioid type endometrial cancer who underwent surgical staging and were found to have pT1a-b disease. Binary logistic regression was used to assess predictors of LN involvement (defined as ITC, micrometastases, or macrometastases). RESULTS: In total, 438 patients with pT1a-b disease were identified. In the overall cohort and in the subset meeting PORTEC-1 inclusion criteria (n = 195), no LVSI was present in 67.4% and 50.8%; focal LVSI was present in 16.7% and 24.1%; and substantial LVSI was present in 16.0% and 25.1%, respectively. Among patients who underwent surgical LN assessment (79.2%, n = 347), LNs were involved in 3.3% without LVSI, 7.5% with focal LVSI (OR 2.4), and 15.2% with substantial LVSI (OR 5.3) (p = .005), with a similar trend in the PORTEC-1 cohort. Extent of LVSI correlated with disease burden in LN metastases. CONCLUSION: Our incidence of substantial LVSI was three to five times higher than reported by PORTEC and correlated with LN involvement. This questions the reproducibility of the three-tier LVSI reporting system and emphasizes the need for multi-institutional data outside PORTEC for confirmation of our findings.
引用
- Pifer PM, Bhargava R, Patel AK, et al. Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? - A single-institution study. Gynecol Oncol. 2020. PMID: 32718729. doi:10.1016/j.ygyno.2020.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。